This is a preview of subscription content, log in via an institution to check access.
Notes
The study was funded by ViroPharma SPRL-BVBA.
Reference
Lee D, et al. The Cost Effectiveness of Licensed Oromucosal Midazolam (Buccolam) for the Treatment of Children Experiencing Acute Epileptic Seizures: An Approach When Trial Evidence is Limited. Pediatric Drugs : 20 Mar 2013. Available from: URL: http://dx.doi.org/10.1007/s40272-013-0009-5
Rights and permissions
About this article
Cite this article
Midazolam oromucosal solution more QALYs at lower cost. PharmacoEcon Outcomes News 675, 8 (2013). https://doi.org/10.1007/s40274-013-0287-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0287-8